SCHEMBL644252

SCHEMBL644252

COc1ccc(S(=O)(=O)N2c3ccccc3CC2C(=O)O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
NPSR1 Q6W5P4 2/20 0.53
LMNA P02545 3/20 0.50
GAA P10253 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
KMT2A Q03164 1/20 0.50
MAPT P10636 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TAS2R14 Q9NYV8 1/20 0.49
MMP1 P03956 3/20 0.48
MMP9 P14780 3/20 0.48
MMP13 P45452 3/20 0.48
ADAM17 P78536 3/20 0.48
NPC1 O15118 1/20 0.48
TSHR P16473 1/20 0.48
CRHBP P24387 1/20 0.48
CRHR2 Q13324 1/20 0.48
MCL1 Q07820 2/20 0.48
BCL2L1 Q07817 1/20 0.48
BAK1 Q16611 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8380984 1.00 ALDH1A1 (0.53) ALDH1A1NPSR1LMNAGAAL3MBTL1
SCHEMBL644486 0.89 ALDH1A1 (0.52) ALDH1A1NPSR1LMNAGAAL3MBTL1
SCHEMBL6010342 0.87 MMP1 (0.61) MMP1MMP9MMP13ADAM17MMP2
SCHEMBL8384891 0.87 MMP1 (0.61) MMP1MMP9MMP13ADAM17MMP2
SCHEMBL926644 0.87 NPSR1 (0.50) ALDH1A1NPSR1LMNAGAAL3MBTL1
SCHEMBL927146 0.87 ALDH1A1 (0.50) ALDH1A1NPSR1LMNAL3MBTL1MCL1
SCHEMBL28751377 0.87 LMNA (0.52) ALDH1A1NPSR1LMNAL3MBTL1MCL1
SCHEMBL18041161 0.86 LMNA (0.67) ALDH1A1NPSR1LMNAL3MBTL1MAPT
SCHEMBL5569768 0.86 LMNA (0.67) ALDH1A1NPSR1LMNAL3MBTL1MAPT
SCHEMBL15280427 0.86 LMNA (0.67) ALDH1A1NPSR1LMNAL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119633-B2 N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases GRUENENTHAL GMBH (DE) 2012-02-21 US disclosed
EP-2150530-B1 SUBSTITUTED SULFONAMIDE DERIVATIVES GRUENENTHAL GMBH (DE) 2011-10-26 EP disclosed
EP-2150530-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-02-10 EP disclosed
US-20080312231-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2008-12-18 US disclosed
WO-2008131947-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO disclosed
EP-0861236-B2 CYCLIC AND HETEROCYCLIC N-SUBSTITUTED ALPHA-IMINOHYDROXAMIC AND CARBOXYLIC ACIDS SANOFI AVENTIS DEUTSCHLAND (DE) 2006-08-16 EP disclosed
US-6815440-B2 FOR THERAPY AND PROPHYLAXIS OF DISORDERS IN THE COURSE OF WHICH IS INVOLVED AN INCREASED ACTIVITY OF MATRIX-DEGRADING METALLOPROTEINASES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-11-09 US disclosed
US-20030176432-A1 Cyclic and heterocyclic N-substituted alpha-iminohydroxamic and -carboxylic acids AVENTIS PHARMA DEUTSCHLAND GMBH. 2003-09-18 US disclosed
US-6573277-B2 Metalloproteinase inhibitor HOECHST AKTIENGESELLSCHAFT (DE) 2003-06-03 US disclosed
EP-0861236-B1 CYCLIC AND HETEROCYCLIC N-SUBSTITUTED ALPHA-IMINOHYDROXAMIC AND CARBOXYLIC ACIDS HOECHST AG (DE) 2002-02-13 EP disclosed
US-20010011134-A1 Cyclic and heterocyclic N-substituted alpha-iminohydroxamic and -carboxylic acids HOECHST AKTIENGESELLSCHAFT 2001-08-02 US disclosed
US-6207672-B1 FOR TREATMENT OF CONNECTIVE TISSUE DISORDERS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-03-27 US disclosed
EP-0861236-A1 CYCLIC AND HETEROCYCLIC N-SUBSTITUTED ALPHA-IMINOHYDROXAMIC AND CARBOXYLIC ACIDS HOECHST AKTIENGESELLSCHAFT (DE) 1998-09-02 EP disclosed
WO-1997018194-A1 CYCLIC AND HETEROCYCLIC N-SUBSTITUTED α-IMINOHYDROXAMIC AND CARBOXYLIC ACIDS HOECHST AKTIENGESELLSCHAFT (DE) 1997-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010011134-A1 Cyclic and heterocyclic N-substituted alpha-iminohydroxamic and -carboxylic acids MMP1, MMP2, HPGD ALDH1A1 45/4885NPSR1 1086/4885LMNA 747/4885
US-20080312231-A1 Substituted Sulfonamide Compounds SULT2A1, SULT1A1, SCN1A ALDH1A1 511/4885NPSR1 39/4885LMNA 2721/4885
US-20030176432-A1 Cyclic and heterocyclic N-substituted alpha-iminohydroxamic and -carboxylic acids MMP1, MMP2, HPGD ALDH1A1 45/4885NPSR1 1086/4885LMNA 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.